ClinicalTrials.gg
Sign In

Hyperphosphatemia clinical trials

The registry lists 173 studies for Hyperphosphatemia across more than 10 countries. 16 are recruiting or about to start. 104 of them are mainly about Hyperphosphatemia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.

Get an email when these change. Save the Hyperphosphatemia studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
121
Status unknown
15
Terminated
14
Recruiting
13
Withdrawn
3
Active, not recruiting
3

Phase

Phase 3
60
Phase 2
34
Phase 4
18
Phase 1
12

Where

United States
56
Japan
41
China
18
United Kingdom
18
Germany
18
France
13

Who runs them

Bayer (10) · Astellas Pharma Inc (8) · Kyowa Kirin Co., Ltd. (7) · Taisho Pharmaceutical Co., Ltd. (7) · Tanabe Pharma Corporation (7) · Ardelyx (6) · Genzyme, a Sanofi Company (6) · Keryx Biopharmaceuticals (6)

What is being tested here

Drugs under test in Hyperphosphatemia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
AP301 peptide122
Sodium phosphate101
Potassium phosphate101
Lanthanum carbonate0616
Ferric citrate0813
Tenapanor0713
Sevelamer0512
Cholebine0910
Bixalomer057
PA21056

Coming up

5phase 3 studies under way
7studies finish main data collection within a year4 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 7, phase 3 first

Who these studies take

Of the 13 Hyperphosphatemia studies recruiting now, 11 (85%) set no upper age limit and 2 (15%) stop at 75 or younger. 4 (31%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (23%) take healthy volunteers.

Recruiting studies that take each age, of 13
AgeWomenMen
103 (23%)3 (23%)
1811 (85%)11 (85%)
3011 (85%)11 (85%)
4011 (85%)11 (85%)
5011 (85%)11 (85%)
6511 (85%)11 (85%)
7511 (85%)11 (85%)
8511 (85%)11 (85%)

Across all 173 studies, recruiting or not: 17% stop at 75 or younger and 10% at 65; 14% take children; 0% are for women only and 1% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hyperphosphatemia studies take

Of 21 phase 3 interventional studies under Hyperphosphatemia, half reached primary completion within 15 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 27 mo6–10 · 13 studies——
Phase 315 mo8–22 · 21 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 11, 2026.

Newly registered1

Studies

Recruiting first, then most recently updated. Showing 50 of 173. Browse all 173 → or search them.